For monitoring minimal residual disease (MRD) in chronic myeloid leukemia (CML) the most recommended method is quantitative RT-PCR (RT-qPCR) for measuring BCR-ABL1 transcripts. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.